# Treatment of Patients With RAD001 With Progressive Sarcoma

> **NCT00767819** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 71 (actual)

## Conditions studied

- Progressive Sarcoma

## Interventions

- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00767819
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-31
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-05-17
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00767819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00767819, "Treatment of Patients With RAD001 With Progressive Sarcoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00767819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*